

**INDEX**

# Subject index to volume 30

## Symbols

2-Octyl cyanoacrylate

bonding strength of, **20, 23**

description, **21**

leak incidence, **22**

leaking pressure, **22**

## A

A-scan biometry

measurement of axial length with, **24**

ABK. *See* aphakic bullous keratopathy

Abscess

orbital

associated factors, **31**

computed tomography findings, **30**

presenting signs, **31**

ACIOL. *See* anterior chamber, intraocular lens

Acrysof, **183**

Acute severe visual-acuity decrease, **55, 57**

ADD-V, **50**

Age

as risk factor for POAG, **154, 156, 157**

association with diabetic retinopathy, **180**

Age-related macular degeneration, **46**

cause of irreversible central visual loss, **116**

description, **47**

incidence of lesion, **59**

neovascular

absence of effective treatment for, **58**

geographic atrophy, **47**

treatment with photodynamic therapy, **47**

Age-related maculopathy, **47**

Agency for Healthcare Research and Quality, **92**

Alcohol consumption

association with POAG, **156**

Allograft

dehydrated human-amniotic-membrane

compared with conjunctival autograft, **166**

description, **167**

grafting after pterygium excision, **166**

transplantation after pterygium excision, **168**

Alpha agonists, **162**

AmbioDry. *See* allograft, dehydrated human-amniotic-membrane

Amikacin, **173**

Aminoglycosides, **173**

Angiogenesis

inhibition by TTT, **118**

Angiography

confocal indocyanine green, **54**

in RPED, **118**

Angle

permanent closure, **164**

Anterior chamber

inflammation, **182**

intraocular lens, association with uveitis, glaucoma,

corneal decompensation, **183**

involvement in glaucoma secondary to retinoblastoma,

**127**

watertight

maintenance in corneal perforations, **21**

Antibiotics

for preseptal and orbital cellulitis, **28, 31, 33**

for bacterial endophthalmitis, **173**

for treatment of endophthalmitis, **18**

intravitreal injection of, **18**

Antibiotic Prophylaxis for Cataract Surgery, **87**

Aphakic bullous keratopathy

indication for penetrating keratoplasty, **148-151**

Aphakic correction, **182**

Apoptosis

caused by TTT, **118**

Argon laser trabeculoplasty, **162**

ARM. *See* age-related macular degeneration

Asia Pacific Congress of Ophthalmology, **6**

Aspirin

association with POAG, **157**

Asthma

association with orbital cellulitis, **32**

Astigmatism

correction with laser, **75**

ASVAD. *See* acute severe visual-acuity decrease

Autograft

conjunctival

after pterygium excision, **167**

compared with allograft, **166**

recurrence rate, **167**

Axial length

measured with corneal diameter and slope, A-scan

biometry, **24, 26-27**

role in IOL-power estimation, **25**

- 
- Cornea  
length measurement, **24**  
measured with A-scan, **26**
- B**
- B-zone peripapillary atrophy  
association with glaucoma, **158**
- Bacteria  
infections associated with orbital and preseptal  
cellulitis, **33**
- Baltimore Eye Survey, **154**
- Bare-sclera resection  
for excision of primary pterygium, **88**  
for pterygium, risk of recurrence, **90**  
with mitomycin C, **90**
- Beaver Dam Eye Study, **155**
- Behcet's disease, **39, 40**
- BES, **155**
- beta-blockers **162, 163**
- Biometry  
use in cataract surgery,
- Blepharoplasty,
- Blindness  
bilateral, due to glaucoma,  
caused by uveitis, **37**  
leading cause of, **154**  
National Prevention Program, **6**  
national survey in the Philippines, **154**  
population-based survey, **98**  
prevention of, **97**  
Third National Survey on, **162**
- Blood pressure  
decrease after administration of tropicamide-  
phenylephrine and tropicamide-phenylephrine, **9**  
diastolic, changes after administration of  
tropicamide-phenylephrine and tropicamide-  
phenylephrine, **10**  
effect of tropicamide-phenylephrine and  
tropicamide-phenylephrine, **7**  
systolic, increase after phenylephrine administration,  
**8**
- Bone resorption  
in cholesterol granuloma, **132**
- Brachytherapy  
for intraocular retinoblastoma, **78**
- Bruch's membrane  
beaks in, **118**  
degeneration of, **118**  
sealing the break in, **116**
- Bullous keratopathy  
indications for penetrating keratoplasty, **148**
- C**
- Carbonic anhydrase inhibitors, **162, 163**
- Cataract  
complication of uveitis, **38, 40**  
evidence-based review of clinical practice guidelines,  
**91**  
surgery complications, **63**  
surgery in diabetic retinopathy, macular edema, **65**
- Cataract  
leading cause of blindness, **154**  
management in patients with diabetes mellitus, **65**  
prevention of postoperative endophthalmitis, **85**  
risk of development in diabetic patients, **63**  
surgery  
estimation of IOL power, **25**
- Cavernous sinus thrombosis  
associated factors, **31**  
computed-tomography findings, **30**  
organisms involved in, **30**  
presenting signs, **31**
- Cellulitis  
complications, **32**  
orbital  
causative agents, **28, 29**  
clinical patterns, **28, 29**  
complications, **29**  
computed-tomography findings, **30**  
etiology, **28**  
management, **28, 29**  
organisms involved, **30**  
presenting signs, **31**  
profile of cases in the Philippines, **32**  
signs and symptoms, **32**  
surgical intervention for, **30, 33**
- preseptal  
antibiotic treatment for, **31**  
associated factors, **29**  
causative agents, **28, 29**  
clinical patterns, **28, 29**  
complications, **29**  
etiology, **28**  
management, **28, 29**  
predisposing factors, **32**  
presenting signs, **28**  
profile of cases in the Philippines, **32**  
surgical intervention for, **33**
- Central-visual-field function, **53**
- Cerebrospinal fluid, **19**
- Chemoreduction  
with adjuvant therapy for retinoblastoma, **79**  
for treatment of retinoblastoma, **80**
- Chemotherapy  
for intraocular retinoblastoma, **78**  
for treatment of intraocular tumors, **81**
- Chemothermotherapy
-

- for intraocular retinoblastoma, **78**
- Chlorhexidine**  
 binding to the corneal epithelium, **121**  
 cytotoxic activity of, **123**  
 efficacy in treatment of keratomycosis, **120**  
 for treatment of filamentous keratomycosis, **119**  
 preparation of 0.2% solution, **120**  
 safety as treatment for keratomycosis, **123**  
 toxicity  
   in cornea, adjacent structures, **119, 120**
- Cholesteatoma**  
 distinguished from cholesterol granuloma, **132**
- Cholesterol**  
 association with diabetic retinopathy, **180**
- Cholesterol granuloma, 129**  
 clinical, radiologic, histopathologic features of, **130**  
 distinguished from  
   acute subperiosteal hematomas, **132**  
   epidermoid cholesteatoma, **132**  
 pathogenesis of, **130**  
 presence of bone resorption in, **132**
- Choroidal melanoma**  
 enucleation, **133**  
 pathogenesis of, **133**
- Choroidal neovascular membrane**  
 presence in RPED, **118**
- Choroidal neovascularization**  
 classic  
   proportion of lesion, **53**  
   reduction in the risk of vision loss, **53**  
 in RPED  
   development, **116**  
   progression, **117**  
 occult  
   evidence from the TAP trial, **52**  
   risk of visual acuity loss in, results from TAP trial, **53**
- CNV. See choroidal neovascularization**
- Coats' disease**  
 association with iris neovascularization, **127**
- Cochrane Central Register of Controlled Trials, 46, 62, 63, 79, 91**
- Colvard infrared pupilometer, 35**
- Combined cataract extraction, 162**
- Comod eye-drop dispenser, 140**
- Computed tomography**  
 use in orbital and preseptal cellulitis, **33**
- Confocal indocyanine green, 54**
- Conjunctival autografting**  
 for excision of primary pterygium, **88**
- Conjunctival hyperemia**  
 with latanoprost use, **84**
- Contrast sensitivity**  
 outcome from the TAP trial, **53**
- Cornea**  
 diameter, slope, **25**  
 lacerations and perforations  
   causes of, **21**  
   sealing  
     use of fibrin glue, **21**  
     use of sutures, **21**  
   treatment options, **21**  
   treatment with 2-Octyl cyanoacrylate, **21**  
 processed and distributed by SLIEBF, **149**  
 toxicity of chlorhexidine in, **119**
- Corneal dystrophies, 149**
- Corneal edema, 182**
- Corneal scar**  
 age distribution of cases, **151**  
 association with trauma, **151**  
 incidence peak, **151**  
 indication for penetrating keratoplasty, **148, 149, 150**
- Corneal stromal dystrophy**  
 indication for penetrating keratoplasty, **149**
- Corneal transplantation, 146**  
*See also*  
   Eye Bank Foundation of the Philippines  
   Republic Act 7885
- Cryotherapy**  
 For intraocular retinoblastoma, **78**
- Cup-disc ratio**  
 basis for glaucoma diagnosis, **165**
- Cyanoacrylate adhesives, 21**
- Cyanoacrylate derivatives**  
 histotoxic effects, **21**
- Cystoid macular edema**  
 complication of uveitis, **38**
- D**
- Dehiscence, 170**
- Diabetes mellitus**  
 association with  
   diabetic retinopathy, **178, 180**  
   orbital cellulitis, **32**  
   POAG, **156, 158**  
 global prevalence of, **63**  
 risk factor for  
   endophthalmitis, **138**  
   glaucoma, **154**
- Diabetic retinopathy**  
 association with  
   age, **180**  
   cholesterol levels, **180**  
   fasting blood glucose, **180**  
   glycosylated hemoglobin, **180**  
   medication, **180**  
   sex, **180**

smoking, **180**  
cause of blindness, **179**  
clinical and angiographic prevalence rates, **178, 180**  
correlation with visual outcome, **63**  
grading system, **179**  
nonproliferative, proliferative, **179**  
prevalence  
    according to fundus examination, **178**  
    among diabetic patients, **178**  
    rates, **179, 180**  
progression  
    after phacoemulsification, **65**  
    effect of phacoemulsification on, **62**  
    in diabetic patients, **63**  
    postoperative, **64**  
Diode cyclo-photocoagulation, **162**  
Disc hemorrhage  
    prevalence in glaucoma, **158**  
DM. *See* diabetes mellitus  
DR. *See* diabetic retinopathy  
Dystrophy  
    Corneal stromal  
        indications for penetrating keratoplasty, **148**  
    Fuch's  
        indications for penetrating keratoplasty, **148**

## **E**

EBFP. *See* Eye Bank Foundation of the Philippines  
EBM. *See* Evidence-based medicine  
Electroretinogram, **174**  
Endophthalmitis  
    after cataract surgery, **137**  
    association with scleral fixation, **183**  
    bacterial, treatment of, **172, 173, 177**  
    blurring of vision in, **137**  
    diagnosis, **137**  
    pain in, **137**  
    preferred treatment, **18**  
    postoperative, prevention of **85**  
    rising trend in, **87**  
    risk factors for, **138**  
    treatment, **137, 138**  
    treatment with pars plana vitrectomy, **137**  
    treatment and prevention of, **19**  
Endophthalmitis Vitrectomy Study, **137, 139, 173**  
Epidemiology  
    of blindness in the Philippines, **98**  
Epithelialization  
    in chlorhexidine-treated rabbit eyes, **121**  
ERG. *See* Electroretinography  
Evidence-Based Clinical Practice Guidelines for the  
    Management of Cataract among Adults, **92**  
Evidence-based medicine

    application in ophthalmology, **73**  
    five steps in the practice of, **74**  
    limitations of, **74**  
    significance in clinical practice, **44**  
Excimer laser, **77**  
Exophthalmos, **12**  
Extracapsular cataract extraction  
    compared with manual small-incision surgery, **91**  
    review of guidelines, **91-92**  
    visual outcome among diabetic patients, **63**  
Extracapsular surgery, **45**  
Eye health  
    policies, **98**  
    promotion of, **4**  
    research in, **97**  
Eye Bank Foundation of the Philippines, **146**  
Eye banking  
    obstacles to, **145**  
    Philippine experience, **145**

## **F**

Fasting blood glucose  
    association with diabetic retinopathy, **180**  
Fat debulking, **13, 15**  
Fibrin glue  
    description of, **167**  
    success rates in conjunctival autografts, **167**  
    use in sealing corneal perforations, **21**  
Fibrosis  
    in upper-eyelid retraction, **15**  
Filtration surgery, **163**  
Fluoroquinolones, **19**  
Fuch's dystrophy **148-151**  
Fundus  
    findings in optic neuritis, **68**

## **G**

Gentamicin  
    for prevention of postoperative endophthalmitis, **87**  
    toxicity of intravitreal injection, **173**  
Glaucoma  
    association with ACIOL, **183**  
    association with IOP, **158**  
    cause of  
        bilateral blindness in the Philippines, **162**  
        low vision in the Philippines, **162**  
        visual impairment in the Philippines, **154**  
    clinical presentation in retinoblastoma, **125**  
    common types seen in a tertiary hospital, **163**  
    complication of uveitis, **38, 40**  
    diagnosis in early stages, **154**  
    drainage-device implantation, **162**  
    effect of age on development of, **157**

factors that affect causation of, **154**  
 indications for penetrating keratoplasty, **148, 148**  
 initial treatment, **163, 164**  
 juvenile, **163**  
 leading cause of irreversible blindness, **154, 162**  
 lens-induced, **161, 163**  
   phacomorphic, phacolytic, **163**  
   profile of patients with, **164**  
 mechanisms in enucleated retinoblastoma eyes **127**  
 medications  
   administration with preservative-free dispenser, **140**  
 neovascular, development in RB, **127**  
 number of Filipinos with, **162**  
 number of Filipinos with visual impairment due to, **154**  
 number of people affected, **162**  
 normal tension, **163**  
 open-angle  
   IOP lowering with latanoprost, timolol, **83**  
 pigmentary, **181**  
 prevalence rates in selected countries, **162**  
 primary angle-closure  
   compared with POAG, **63-64**  
   most common initial treatment for, **161**  
   profile of patients with, **164**  
 primary open-angle  
   association with  
     age, **156-157**  
     aspirin use, **157**  
     family history, **157**  
     intraocular pressure, **158**  
     sex, **157**  
     smoking, **157**  
     systemic diseases, **156-157**  
     vertical cupping, **156**  
     visual-field loss, **156**  
   incidence compared with PACG, **162**  
   most common initial treatment for, **161**  
   risk factors for, among Filipinos, **153**  
   treatment with latanoprost, timolol, **82**  
   profile of patients with, **164**  
 profile of cases at a tertiary institution, **161**  
 secondary, **163**  
 secondary to retinoblastoma, **124, 125**  
   common mechanisms, **124**  
   management, **127**  
 suspects, **163-165**  
 worldwide incidence, **154**  
 Glaucomatous optic neuropathy **154-156, 163**  
 Glycosylated hemoglobin  
   association with diabetic retinopathy, **180**  
 GON. *See* glaucomatous optic neuropathy  
 Goniotomy, **162**

Graft dehiscence, **166**  
 Granuloma  
   after conjunctival autograft, **170**  
 Graves' ophthalmopathy, **12-13, 15-16**

## H

HAIOL. *See* intraocular lenses, hydrophobic acrylic  
 Heart disease  
   association with POAG, **156**  
 Heart rate  
   with use of tropicamide, phenylephrine, **7, 11**  
 Helen Keller International, **97**  
 Hypertension  
   association with POAG, **153, 156, 158**  
   risk factor for glaucoma, **154**  
 Hyperthermia  
   and TTT, **118**  
 Hypotony  
   complication of uveitis, **40**

## I

Idiopathic pars planitis, **39**  
 IFETB. *See* International Federation of Eye and Tissue  
   Banks  
 Infection  
   of eyelid  
     predisposing factor for preseptal cellulitis, **32**  
 Infectious keratitis  
   fungal etiology, **150**  
 Inflammation  
   in rabbit eyes treated with chlorhexidine, **121**  
   of cornea resulting from the application of  
     chlorhexidine gluconate, **123**  
 Institute of Ophthalmology, **97**  
 International Federation of Eye and Tissue  
   Banks, **146**  
 International Uveitis Study Group, **38**  
 Intraocular lens  
   anterior-chamber, **182**  
   hydrophobic acrylic, implantation in the ciliary  
     sulcus, **181-182**  
     association with PDS and PG, **183-184**  
   implantation for aphakic correction, **182**  
   in-the-bag implantation with phacoemulsification, **65**  
   iris-fixated, **183**  
   polymethylmethacrylate, **182**  
   power estimation, **25, 27**  
 Intraocular pressure  
   association with glaucoma, POAG, **156-158**  
   elevated  
     complication of orbital and preseptal cellulitis, **32**  
     risk factor for POAG, **154**  
   increase in retinoblastoma, **125, 127**

lowering  
agents for, **162**  
effect on glaucoma incidence, progression, **158**  
measurement, as screening tool for glaucoma, **154**  
reduction with latanoprost, timolol, **83**  
transient rise, **182**  
uncontrolled, **163**

Intraretinal microvascular abnormality, **179**

Intravenous methylprednisolone  
Side effects of, **71**  
treatment for optic neuritis **68-69**  
versus oral prednisone for optic neuritis, **67**  
visual outcomes in optic-neuritis patients, **70**

IOL. *See* intraocular lens

IOP. *See* intraocular pressure

Iris  
neovascularization  
association with retinoblastoma, **125**  
factors leading to, **126**  
in retinoblastoma  
diagnosis, **128**  
pigmentation with latanoprost use, **84**  
pigmented, chafing of, **184**

Ischemia  
risk factor for POAG, **154**

IVMP. *See* methylprednisolone, intravenous

## K

Keratitis  
treatment with chlorhexidine, **122-123**

Keratoconjunctivitis sicca, **21**

Keratoconus  
indication for PKP, **148-151**

Keratometer, **25**

Keratocystosis  
cause of ocular morbidity, **120**  
difficulty of cure, **120**  
treatment with chlorhexidine gluconate, **119**

Keratopathy, **21**

## L

Laser  
iridotomy, **162**  
iridoplasty, **162**  
trabeculoplasty, **162**  
photocoagulation  
for intraocular retinoblastoma, **78**

Laser in situ keratomileusis  
complications and side effects, **77**  
for myopia correction, **75, 77**  
safety and efficacy, **76**

Laser-assisted in situ keratomileusis, **35**

LASIK. *See* Laser in situ keratomileusis

Latanoprost  
IOP lowering with, **83**  
compared with timolol  
for POAG, **82**  
randomized controlled trial, **83**

Lens extraction, **163**

Leukostasis  
caused by TTT, **118**

Levator, **13**

Levator aponeurosis, **12**

Lid retraction  
causes of, **13**  
in patients with Grave's ophthalmology, **12**

Linezolid  
compared with other other antibiotics, **173**  
described, **173**  
effects on ERG, **175**  
histopathologic changes with, **175, 176**  
safety of intravitreal injection, **172**

## M

Macular degeneration, **182**

Macular edema  
postoperative progression in diabetic patients, **63**

Macular Photocoagulation Study, **116**

Mean defect  
association with POAG **153, 156**

Membrane  
human amniotic  
processing of, **167**  
transplantation of, **167**

Metamorphopsia  
in RPED, **116**

Microaneurysms, **179**

Microbial keratitis  
age distribution of cases, **151**  
association with trauma, **151**  
indication for PKP, **148, 149, 150**  
leading to corneal perforation, **21**

Migraine  
association with POAG, **156, 158**  
risk factor for glaucoma, **154**

Mitomycin C  
adjuvant treatment for excision of primary  
pterygium, **88**

Moorfields Macular Study Group, **116**

Moxifloxacin  
intravitreal injection of, **19**  
retinal toxicity of, **17, 18**  
side effects of systemic use, **19**

Muller muscle  
overaction, **13**  
recession

for mild to moderate upper-eyelid retraction, **12-16**  
Multifocal choroiditis **39**  
Multiple sclerosis  
development of, **72**  
development after treatment of optic neuritis with  
IVMP and oral prednisone, **70-71**  
similarity of MRI findings with optic neuritis, **68**  
Mydriasis, **8**  
Myopia  
and POAG prevalence, **154**  
association with POAG, **157**  
correction with laser, **75**  
correction with LASIK, **77**  
relationship to glaucoma, **156**

## N

N-Butyl-2-cyanoacrylate  
bonding strength of, **20, 23**  
use in sealing corneal perforations, **21**  
leaking pressure, leak incidence, **22**  
Natamycin  
compared with chlorhexidine, **120**  
National Society for the Prevention of Blindness, **5**  
Neovascular-membrane morphology, **54**  
Neovascularization  
classic choroidal, **53**  
due to ARMD, **47**  
occult choroidal, **52**  
of the iris, in glaucoma secondary to retinoblastoma,  
**124**  
subfoveal choroidal, **50**  
NVI. *See* iris neovascularization  
Nylon 10-0  
bonding strength of, **20**

## O

ONH. *See* optic-nerve head  
ONTT. *See* Optic Neuritis Treatment Trial  
Ophthalmological Society of the Philippines **5**  
Ophthalmology  
development as a separate specialty, **5**  
organized, history in the Philippines, **4**  
pillars of Philippine, **98**  
Optic cupping  
association with POAG, **156**  
Optic disc  
vertical cupping  
association with POAG, **153**  
Optic nerve  
disorder of, **68**  
involvement in RB with secondary glaucoma, **127**  
Optic-nerve head  
structural changes, association with POAG, **154**

parameters, association with glaucoma, **158**  
Optic neuritis  
common presentation, **68**  
complication of uveitis, **40**  
monosynaptic, **68**  
recovery of vision, **71**  
recurrence, **67, 71**  
recurrence after treatment  
with IVMP, **70**  
oral prednisone, **70**  
treatment with steroids, **67-68**  
Optic Neuritis Treatment Trial, **68-71**  
Optic neuropathy  
glaucomatous, **154**  
Orbit  
cholesterol granuloma of, **129**

## P

PACG. *See* glaucoma, primary angle-closure  
Pain  
acute, symptom of glaucoma, **164**  
comparison in amniotic-membrane allograft and  
conjunctival autograft, **170**  
Panuveitis, **37, 39**  
Pars plana vitrectomy, **162**  
treatment for endophthalmitis, **137**  
Pattern standard deviation  
association with POAG, **153, 156-157**  
PBK. *See* pseudophakic bullous keratopathy  
PCR. *See* posterior-capsule rupture  
PDS. *See* pigment-dispersion syndrome  
PDT. *See* photodynamic therapy  
Penetrating keratoplasty  
leading indications for, **148**  
leading indications in developed world, **150**  
leading indications in developing countries, **150**  
main indications for, **149**  
Phacoemulsification  
progression of diabetic retinopathy after, **65**  
effect on progression of diabetic retinopathy, **62**  
posterior-capsule rupture during, **181**  
prevention of endophthalmitis after, **86**  
review of clinical-practice guidelines, **91-92**  
stop-and-chop, **182**  
worldwide implementation, **44**  
Phenylephrine  
adverse systemic reactions **8**  
cardiovascular actions of, **8**  
combined with tropicamide  
pressor and mydriatic effects, **7**  
dilation per unit time, **11**  
mydriatic effect, **10**  
Philippine Ophthalmological and Otolaryngological

Society, **5**  
 Philippine Academy of Ophthalmology, **4, 6**  
 Philippine Academy of Ophthalmology and Otolaryngology, **5**  
 Philippine Board of Ophthalmology, **6**  
 Philippine Board of Ophthalmology and Otolaryngology, **5**  
 Philippine Eye Bank for Sight Restoration, **5**  
 Philippine Eye Research Institute, **97**  
 Philippine Journal of Ophthalmology, **5**  
 Philippine Journal of Ophthalmology and Otolaryngology, **5**  
 Philippine Society of Ophthalmology, **5**  
 Photodynamic therapy  
   adverse effects, **55**  
   cost-effectiveness, **59**  
   for neovascular ARMD, **46**  
   implications for health services, **60**  
   in people with choroidal neovascularization, **47**  
   prevention of visual loss, **59**  
   with verteporfin versus placebo, **51, 52**  
   with verteporfin, economic benefits, **59**  
 Photodynamic therapy study (TAP), **116**  
 Pigment-dispersion syndrome  
   incidence after HAIOL implantation, **182**  
 Pigmentary glaucoma  
   incidence after HAIOL implantation, **182**  
 PKP. *See* penetrating keratoplasty  
  
 PMMA. *See* intraocular lens, polymethylmethacrylate  
 POAG. *See* primary open-angle glaucoma  
 Posterior-capsule rupture, **181-183**  
 Povidone-iodine  
   for prevention of postoperative endophthalmitis, **86**  
 Prednisone  
   oral  
     treatment for optic neuritis, **69**  
     versus intravenous methylprednisolone, **67**  
 Proptosis, **15**  
   in orbital cellulitis, **30**  
 Prostaglandin analogs, **162**  
 Pseudophakia, **183**  
 Pseudophakic bullous keratopathy  
   indication for PKP, **148-151**  
   age distribution of cases, **151**  
   peak of incidence, **151**  
 Pterygium  
   use of dehydrated human-amniotic-membrane allograft versus conjunctival autograft after excision, **167-171**  
   prevention of recurrence, **88**  
   primary, surgical interventions for, **88**  
   risk of recurrence, **89**

surgical treatment options, **88**  
 technique of excision, **168**  
 Pupil  
   changes in size  
     after administration of tropicamide 0.5% + phenylephrine, **10-11**  
   dilation with phenylephrine, tropicamide, **8**  
   size determination, **34**  
     using digital camera, **35**  
     with infrared video camera, **35**  
 Pupillary block  
   mechanism of glaucoma in retinoblastoma, **127**  
   angle closure due to, **163**

## R

RB. *See* retinoblastoma  
 Reepithelialization  
   in rabbit eyes after chlorhexidine administration, **119**  
 Refraction  
   association with POAG, **156**  
 Refractive error  
   association with POAG, **157**  
 Refractive surgery  
   Safety and efficacy, **77**  
 Regraft  
   indication for PKP, **148-151**  
   rate of, **151**  
 Republic Act 7885, **146**  
 Retina  
   scarring, **47**  
   signs associated with ARMD, **47**  
 Retinal detachment  
   complication of uveitis, **38, 40**  
 Retinal pigment epithelium, **47**  
   proliferation caused by TTT, **118**  
   reduction in size after TTT, **117**  
 Retinal toxicity, **172**  
 Retinal-pigment epithelial detachment  
   associated with ARMD, **117**  
   clinical course of, **117**  
   consequences of, **116**  
   in neovascular age-related macular degeneration, **116**  
   treatment with TTT, **115, 118**  
 Retinoblastoma  
   association with secondary glaucoma, **125**  
   clinical trials in the treatment of, **79**  
   in children manifesting at older age, **127**  
   intraocular  
     globe-sparing interventions, **78**  
     with secondary glaucoma, **124**  
 Retinopathy of prematurity  
   association with iris neovascularization, **127**  
 Rosenbaum chart, **35**



Rosenbaum-pupil-comparison, **34**  
RPE. *See* retinal pigment epithelium  
RPED. *See* retinal-pigment epithelial detachment

## S

Santa Lucia International Eye Bank of Manila, **145-146**  
Scanning Laser Ophthalmoscope, **53**  
Sclerosis  
    caused by TTT, **118**  
Sentro Oftalmologico Jose Rizal, **147**  
Serum-creatinine  
    correlation with diabetic retinopathy, **180**  
Sex  
    association with POAG, **157**  
Sight  
    importance of, **4**  
Silicone polypropylene foldable lenses  
    association with endophthalmitis, **138**  
Sinus  
    involvement in orbital cellulitis, **31**  
Sinusitis  
    association with orbital and preseptal cellulitis, **32**  
SLIEB. *See* Santa Lucia International Eye Bank  
Small-incision sutureless cataract surgery, **45**  
Smoking  
    association with  
        diabetic retinopathy, **180**  
        POAG, **156**  
Sta. Lucia International Eye Bank Foundation, **148**  
Staphylococcus sp.  
    involvement in orbital and preseptal cellulitis, **32**  
Steroid  
    association with POAG, **156**  
    treatment for optic neuritis, **68**  
Steven Johnson Syndrome, **149**  
Subretinal neovascular membranes, **47**  
Surell's formula  
    for computing axial length, **24, 27**  
    for computation of IOL power, **25**  
Surgery  
    for orbital and preseptal cellulitis, **33**

## T

TAP 1999, **49-55, 56, 58, 116**  
Tarsorrhaphy  
    lateral, **13**  
    for management of Graves' ophthalmopathy, **15**  
Tenon's capsule, **168**  
Thermotherapy  
    for treatment of intraocular tumors, **81**  
Thyroid disease  
    association with POAG, **156, 158**

    risk factor for glaucoma, **154**  
Timolol  
    compared with latanoprost  
        for POAG, **82**  
        randomized controlled trial, **83**  
    IOP lowering in POAG, **83**  
Toxicity  
    of chlorhexidine on the cornea, **119**  
Toxocara  
    cause of uveitis, **40**  
Toxoplasma  
    cause of uveitis, **40**  
Trabeculectomy, **162-163**  
Transpupillary thermotherapy  
    association with vascular thrombosis, **118**  
    described, **118**  
    for neovascular ARMD, **116**  
    for retinal-pigment epithelial detachment, **115, 118**  
    for retinoblastoma, **78**  
    techniques of, **116**  
    described, **118**  
Trauma  
    association with microbial keratitis, corneal scar, **151**  
    association with orbital and preseptal cellulitis, **32**  
    cause of corneal lacerations, **21**  
    incidence among males, **151**  
    indication for PKP, **149, 151**  
Tropicamide  
    cardiovascular actions of, **8**  
    combined with phenylephrine  
        pressor and mydriatic effects, **7, 10**  
        dilation per unit time, **11**  
TTT. *See* transpupillary thermotherapy  
Tuberous sclerosis  
    description, **141**  
    diagnosis, **141**  
    ophthalmic features of, **141**  
Tumor  
    Intraocular, **78**  
    *See also* retinoblastoma

## U

Ultrasound, **25**  
Upper-eyelid retraction  
    in Graves' ophthalmopathy, **13**  
    secondary to Graves' disease, **12, 15**  
Uveitis  
    age at presentation, **40**  
    association with ACIOL, **183**  
    changes in patterns over time, **40**  
    cause of blindness, **41**  
    defined, **38**  
    endogenous

---

---

defined, **38**  
distribution and clinical characteristics, **37**  
etiologies, **39**  
idiopathic anterior, **39**  
infectious causes, **40**  
ocular complications and blindness, **37**  
patterns in a Philippine eye clinic, **37**  
profile among Filipino patients, **39**  
profile of Filipino patients with, **38**  
sight-threatening complications, **38, 40, 41**  
systemic medication for, **40**  
treatment, **38**  
    with immunosuppressive drugs, **41**  
tuberculous, **40**

## V

Vacuolization, **175-176**

Vancomycin

    caution against routine use for prophylaxis, **87**  
    for prevention of postoperative endophthalmitis, **86**  
    treatment for endophthalmitis, **138**

Vascular thrombosis

    caused by TTT, **118**

Verteporfin

    safety and effectiveness, **50**  
    in photodynamic therapy study, **116**

Vertical cupping

    association with POAG, **153, 156-157**

Videoangiography

    fluorescein

        diagnostic adjunct in RPED, **118**

    indocyanine green, **116**

    sodium, **116**

VIP 2001, **49, 50-58, 116**

Viral infection

    indication for PKP, **150-151**

Vision

    loss in

        ARMD, **47**

        untreated PACG, **163**

Visual acuity

    association with POAG, **153, 156-157**

    change after TTT, **115, 117**

    relationship to glaucoma, **156**

    decrease with PDT, **59**

Visual field

    mean defect

        association with POAG, **156**

    pattern standard deviation

        association with POAG, **156-157**

Visudyne, **50**

Vitreous hemorrhage

    complication of uveitis, **38, 40**

Vogt-Koyanagi-Harada syndrome

    diagnosis and treatment, **134**

    diagnostic criteria, **134**

    etiology and pathogenesis, **134**

    stages, **135**

    treatment, **135**